Loading
Life sciences · Journal article
Next Nanotechnology · November 7, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Targeted drug delivery systems offer a promising strategy to enhance anticancer efficacy while minimizing systemic side effects. In this study, a multifunctional nanocarrier based on magnetic mesoporous silica nanoparticles was developed for the targeted delivery of quercetin. Fe₃O₄ nanoparticles were incorporated into mesoporous silica, followed by surface coating with polydopamine, conjugation of folic acid as a targeting ligand, and loading of quercetin. The successful stepwise modification of the nanoparticles was confirmed by FESEM, BET, FTIR, XRD, Zeta potential, PSA, and TGA analyses. The final formulation (Si-Fe-Q-D-F) exhibited a mesoporous structure with reduced pore size and surface area after drug loading and ligand conjugation. In vitro cytotoxicity evaluation using the MTT assay revealed that the drug-free carrier was highly biocompatible, whereas Si-Fe-Q-D-F showed superior anticancer activity against MCF-7 cells, with an IC₅₀ value of approximately 19 µg/mL after 48 h, significantly lower than that of free quercetin (57 µg/mL). The clonogenic assay further showed strong, dose-dependent inhibition of long-term colony formation by Si-Fe-Q-D-F. Moreover, the nanocarrier showed pH-responsive drug release, with accelerated quercetin release at pH 5.0 than at physiological pH. These findings indicate that folic acid-functionalized magnetic mesoporous silica nanoparticles are a promising multifunctional platform for targeted, controlled delivery of quercetin in breast cancer therapy.